Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 8
1990 4
1991 3
1992 1
1993 2
1994 2
1995 3
1997 1
1998 1
1999 1
2000 3
2001 1
2002 4
2003 2
2004 6
2005 8
2006 8
2007 7
2008 8
2009 3
2010 7
2011 4
2012 4
2013 4
2014 3
2015 1
2016 3
2017 2
2019 3
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

102 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Correction of anemia with epoetin alfa in chronic kidney disease.
Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators. Singh AK, et al. N Engl J Med. 2006 Nov 16;355(20):2085-98. doi: 10.1056/NEJMoa065485. N Engl J Med. 2006. PMID: 17108343 Free article. Clinical Trial.
BACKGROUND: Anemia, a common complication of chronic kidney disease, usually develops as a consequence of erythropoietin deficiency. Recombinant human erythropoietin (epoetin alfa) is indicated for the correction of anemia a …
BACKGROUND: Anemia, a common complication of chronic kidney disease, usually develops as a consequence of erythr …
Evaluation of the safety and immunogenicity of subcutaneous HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in predialysis and dialysis patients
.
Casadevall N, Dobronravov V, Eckardt KU, Ertürk S, Martynyuk L, Schmitt S, Schaffar G, Rudy A, Krendyukov A, Ode M. Casadevall N, et al. Clin Nephrol. 2017 Oct;88(10):190-197. doi: 10.5414/CN109159. Clin Nephrol. 2017. PMID: 28766493 Free PMC article.
AIM: To assess the safety and immunogenicity of subcutaneous (SC) HX575 (epoetin-α) in dialysis- and nondialysis-dependent adult patients with chronic kidney disease (CKD). ...CONCLUSIONS: SC HX575 was effective for correcting and maintaining …
AIM: To assess the safety and immunogenicity of subcutaneous (SC) HX575 (epoetin-α) in dialysis- and nondialysis-dependent adult pati …
Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
Provenzano R, Besarab A, Wright S, Dua S, Zeig S, Nguyen P, Poole L, Saikali KG, Saha G, Hemmerich S, Szczech L, Yu KH, Neff TB. Provenzano R, et al. Am J Kidney Dis. 2016 Jun;67(6):912-24. doi: 10.1053/j.ajkd.2015.12.020. Epub 2016 Feb 2. Am J Kidney Dis. 2016. PMID: 26846333 Free article. Clinical Trial.
SETTING & PARTICIPANTS: Patients with stable end-stage renal disease treated with hemodialysis who previously had hemoglobin (Hb) levels maintained with epoetin alfa. ...CONCLUSIONS: In this phase 2 study of anemia therapy in patients with e …
SETTING & PARTICIPANTS: Patients with stable end-stage renal disease treated with hemodialysis who previously had hemoglob …
Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.
McCullough PA, Barnhart HX, Inrig JK, Reddan D, Sapp S, Patel UD, Singh AK, Szczech LA, Califf RM. McCullough PA, et al. Am J Nephrol. 2013;37(6):549-58. doi: 10.1159/000351175. Epub 2013 May 25. Am J Nephrol. 2013. PMID: 23735819 Free article. Clinical Trial.
BACKGROUND: Recombinant erythropoietin has become a routine component of care of patients with chronic kidney disease reducing the need for blood transfusions but raising the risks for cardiovascular events. We undertook this secondary analysis of subjects en …
BACKGROUND: Recombinant erythropoietin has become a routine component of care of patients with chronic kidney disease r …
Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial.
Locatelli F, Hannedouche T, Fishbane S, Morgan Z, Oguey D, White WB. Locatelli F, et al. Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1701-1710. doi: 10.2215/CJN.01380219. Epub 2019 Aug 16. Clin J Am Soc Nephrol. 2019. PMID: 31420350
BACKGROUND AND OBJECTIVES: Erythropoiesis-stimulating agents correct anemia of CKD but may increase cardiovascular risk. We compared cardiovascular outcomes and all-cause mortality associated with monthly methoxy polyethylene glycol-epoetin beta with those of …
BACKGROUND AND OBJECTIVES: Erythropoiesis-stimulating agents correct anemia of CKD but may increase cardiovascular risk. We co …
Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility.
Davis-Ajami ML, Wu J, Downton K, Ludeman E, Noxon V. Davis-Ajami ML, et al. Biologics. 2014 Apr 16;8:155-67. doi: 10.2147/BTT.S27578. eCollection 2014. Biologics. 2014. PMID: 24790409 Free PMC article. Review.
Epoetin zeta was granted marketing authorization in October 2007 by the European Medicines Agency as a recombinant human erythropoietin erythropoiesis-stimulating agent to treat symptomatic anemia of renal origin in adult and pediatric patients on hemodialysi
Epoetin zeta was granted marketing authorization in October 2007 by the European Medicines Agency as a recombinant human erythropoiet
Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: an overview.
Dowling TC. Dowling TC. Am J Health Syst Pharm. 2007 Jul 1;64(13 Suppl 8):S3-7; quiz S23-5. doi: 10.2146/ajhp070181. Am J Health Syst Pharm. 2007. PMID: 17591994 Review.
PURPOSE: The prevalence of chronic kidney disease (CKD) and anemia in the United States, classification scheme for CKD, definition of anemia, etiology and consequences of anemia in patients with CKD, and the clinical and economic benefits …
PURPOSE: The prevalence of chronic kidney disease (CKD) and anemia in the United States, classification scheme f …
The effect of maintaining high hemoglobin levels on long-term kidney function in kidney transplant recipients: a randomized controlled trial.
Tsujita M, Kosugi T, Goto N, Futamura K, Nishihira M, Okada M, Hiramitsu T, Narumi S, Uchida K, Takeda A, Morozumi K, Maruyama S, Watarai Y. Tsujita M, et al. Nephrol Dial Transplant. 2019 Aug 1;34(8):1409-1416. doi: 10.1093/ndt/gfy365. Nephrol Dial Transplant. 2019. PMID: 30561729 Free PMC article. Clinical Trial.
BACKGROUND: Posttransplant anemia may be a major determinant of chronic allograft nephropathy. However, the impact of correcting anemia on graft function remains controversial. ...CONCLUSION: This prospective study suggests that correcting an
BACKGROUND: Posttransplant anemia may be a major determinant of chronic allograft nephropathy. However, the impact of corre
Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients.
Rossert J, Gassmann-Mayer C, Frei D, McClellan W. Rossert J, et al. Nephrol Dial Transplant. 2007 Mar;22(3):794-800. doi: 10.1093/ndt/gfl716. Epub 2007 Jan 8. Nephrol Dial Transplant. 2007. PMID: 17210593 Clinical Trial.
BACKGROUND: The required erythropoiesis-stimulating agent (ESA) dose varies when correcting anaemia in chronic kidney disease (CKD) patients. ...METHODS: This analysis was a post hoc evaluation of epoetin alfa dosage requirements i …
BACKGROUND: The required erythropoiesis-stimulating agent (ESA) dose varies when correcting anaemia in chronic kidne
[Characteristics of anaemia treatment in children with chronic kidney disease].
Puretić Z. Puretić Z. Acta Med Croatica. 2009 Sep;63 Suppl 1:27-32. Acta Med Croatica. 2009. PMID: 20235352 Croatian.
In children with chronic kidney disease anaemia is seen very often. Depending of etiology and the degree of renal insufficiency is found up to 80%. ...In most of children with chronic kidney disease plasma level of er …
In children with chronic kidney disease anaemia is seen very often. Depending of etiology and the degree of r
102 results
Jump to page
Feedback